Status:
COMPLETED
Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112
Lead Sponsor:
Addpharma Inc.
Conditions:
Pain
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
A phase I clinical trial to evaluate the pharmacokinetic interactions and safety between AD-2111 and AD-2112
Detailed Description
Purpose: pharmacokinetic interactions and safety of AD-2111 and AD-2112 in healthy adult volunteers Condition or disease : Pain Intervention/treatment Drug : AD-2111(Celecoxib 200mg), AD-2112(Tramadol...
Eligibility Criteria
Inclusion
- Healthy Adult aged 19 and more at the time of screening visit
- Body mass index (BMI) between 18.5 kg/m2 and 27.0 kg/m2 at the time of screening visit
Exclusion
- As a result of laboratory tests, the following figures: ALT or AST or total bilirubin \> 1.5 times upper limit of normal range
- As a result of laboratory tests, the following figures: Creatinine clearance \< 80mL/min
Key Trial Info
Start Date :
May 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 16 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04375865
Start Date
May 30 2020
End Date
July 16 2020
Last Update
November 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kyungpook National University Hospital
Daegu, South Korea, 41944